Secondary Cytoreductive Surgery May Benefit Platinum-Sensitive Ovarian Cancer Patients
Results were positive
Dr. Sehouli's team found that 72.5% of their enrolled patients really did have completely resected tumors. They also found that there was a slightly longer progression-free survival in surgical patients versus chemotherapy alone. Those who received surgery had a median progression-free survival of about 20 months whereas those who received on chemotherapy were looking at 14. Median time to begin the first subsequent therapy was also longer in the surgical patients, at 21 months versus 13.9 months for the those treated with chemotherapy alone.
